We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Paige Secures Further $20M Funding in Mission to Transform Cancer Diagnosis
Product News

Paige Secures Further $20M Funding in Mission to Transform Cancer Diagnosis

Paige Secures Further $20M Funding in Mission to Transform Cancer Diagnosis
Product News

Paige Secures Further $20M Funding in Mission to Transform Cancer Diagnosis


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Paige Secures Further $20M Funding in Mission to Transform Cancer Diagnosis"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Paige, a company specializing in computational pathology, has announced it received an additional $15M from Goldman Sachs Merchant Banking Division, totaling $20M from the firm. The funding will be added to previously announced Series B financing, bringing the total round to $70M, including an additional investment from Healthcare Venture Partners of $5M on top of their previous $10M investment. The funding brings the Company’s total capital raised to over $95M. Paige will use this new capital to further accelerate its global leadership position in transforming pathology workflows in the field of cancer, while working closely with biopharma companies to create custom diagnostic and clinical trial solutions to improve patient care.

“We appreciate the continued recognition and support we’ve received from Goldman Sachs as we gain traction and prove early results in the clinical and biopharma space,” said Leo Grady, Ph.D., CEO of Paige. “This new funding will help ensure that the Paige Platform and our advanced computational pathology products will drive the next generation of pathology and improve cancer care globally.” 

Advertisement